DEXCOM INC (DXCM) Form 10-Q — Oct 29, 2026
Dexcom's Q3 2026 revenue rose 11% year over year to $1.34 billion, with gross margin expanding to 64% and operating income up 35% to $327.2 million. Net income dipped 3% to $275.1 million, but only because prior-year results included an $82.5 million equity investment gain that did not repeat. The company disclosed a new $1.00 billion share repurchase authorization for 2027 in subsequent events, after completing its prior $1.00 billion 2026 program in Q3, having bought 13.2 million shares year to date. Dexcom also terminated and replaced its credit agreement with a new $200 million five-year revolver maturing September 2031, with no borrowings outstanding.
Key figures
- Eps
- 0.72
- Revenue
- 1344.5
- Net Income
- 275.1
- Revenue Yoy
- 11%
- Cash Position
- 961.4
- Shares Outstanding
- 372950922
- 2026 buyback
- $1.00B completed in Q3 2026 (13.2M shares YTD)
- Gross profit q3
- $864.4M, up 18% YoY, 64% of revenue
- Nine month revenue
- $3,844.8M, up 13% YoY
- Operating income q3
- $327.2M, up 35% YoY
- Nine month net income
- $723.7M, up 27% YoY
- Convertible notes 2028
- $1.25B principal, 0.375% coupon, $162.41 conversion price
- Operating cash flow 9m
- $1,120.4M
- Revolving credit facility
- $200.0M, matures September 2031, no borrowings outstanding
- 2027 buyback authorization
- $1.00B, October 2026, through Dec 31, 2027
- Q3 inventory reserve charges
- $33.0M
- Cash and marketable securities
- $1.82 billion
- Treasury purchases q3 avg price
- $86.32 per share (4,633,657 shares in August)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.